Samsung Medical Center: Lymphoma, T-Cell, Peripheral trials

The registry lists 14 Lymphoma, T-Cell, Peripheral studies with Samsung Medical Center as lead sponsor. 0 are open to participants now and 1 have results posted.

Phase 1 2Phase 2 9No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Concomitant Chemo-radiotherapy Plus VIDL Chemotherapy in NK/T-cell LymphomaCompletedNCT01007526Phase 2Results posted
• Phase II of Lenalidomide After Salvage Therapy in R/R Non-Hodgkin T-cell LymphomaStatus unknownNCT03730740Phase 2
• Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell LymphomaCompletedNCT03487133Phase 2
• Pralatrexate for Relapsed or Refractory Peripheral T-cell LymphomaCompletedNCT03356678
• Intercontinental Cooperative Non-Hodgkin T-cell Lymphoma Prospective Registry StudyCompletedNCT02691351
• VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)Status unknownNCT02544425Phase 2
• Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCLStatus unknownNCT02445404Phase 2
• Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell LymphomaCompletedNCT02424045Phase 2
• International Extranodal NK/T-cell Lymphoma ProjectCompletedNCT02386813
• Gemcitabine in NK/T Cell LymphomaCompletedNCT01660568
• Retrospective Analysis of Skin/Soft Tissue Primary NK/T Cell LymphomaCompletedNCT01341119
• Concomitant Chemo-radiotherapy Followed by MIDLE Chemotherapy in Stage I/II Extranodal NK/T-cell LymphomaCompletedNCT01238159Phase 2
• RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell LymphomasCompletedNCT01198665Phase 1/2
• Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell LymphomasCompletedNCT00374699Phase 1/2